Abstract
Proteins of the tumour necrosis factor (TNF) family are implicated in the regulation of essential cell processes such as proliferation, differentiation, survival and cell death. Altered expression of TNF family members is often associated with pathological conditions such as autoimmune disease and cancer. The TNF-like ligand APRIL (A PRoliferation Inducing Ligand), first described in 1998, was named for its capacity to stimulate tumour cell proliferation in vitro. APRIL expression was initially reported in haematopoietic cells in physiological conditions, and it is overexpressed in certain tumour tissues. APRIL is now known to be involved in activation and immune responses of B cells, as well as in B cell malignancies. This review focuses on recent advances in understanding APRIL and its receptors in physiology and tumour pathology, including the accumulating evidence that specific Toll-like receptor ligands can trigger APRIL-mediated responses, and the identification of new sources of APRIL such as epithelial cells and tumour- infiltrating neutrophils.
Keywords: APRIL, BLyS, BAFF, immunity, B-cell malignancies, tumours, lymphoma
Current Molecular Medicine
Title: The Expanding Role of APRIL in Cancer and Immunity
Volume: 8 Issue: 8
Author(s): Lourdes Planelles, Jan Paul Medema, Michael Hahne and Gijs Hardenberg
Affiliation:
Keywords: APRIL, BLyS, BAFF, immunity, B-cell malignancies, tumours, lymphoma
Abstract: Proteins of the tumour necrosis factor (TNF) family are implicated in the regulation of essential cell processes such as proliferation, differentiation, survival and cell death. Altered expression of TNF family members is often associated with pathological conditions such as autoimmune disease and cancer. The TNF-like ligand APRIL (A PRoliferation Inducing Ligand), first described in 1998, was named for its capacity to stimulate tumour cell proliferation in vitro. APRIL expression was initially reported in haematopoietic cells in physiological conditions, and it is overexpressed in certain tumour tissues. APRIL is now known to be involved in activation and immune responses of B cells, as well as in B cell malignancies. This review focuses on recent advances in understanding APRIL and its receptors in physiology and tumour pathology, including the accumulating evidence that specific Toll-like receptor ligands can trigger APRIL-mediated responses, and the identification of new sources of APRIL such as epithelial cells and tumour- infiltrating neutrophils.
Export Options
About this article
Cite this article as:
Planelles Lourdes, Medema Paul Jan, Hahne Michael and Hardenberg Gijs, The Expanding Role of APRIL in Cancer and Immunity, Current Molecular Medicine 2008; 8 (8) . https://dx.doi.org/10.2174/156652408786733711
DOI https://dx.doi.org/10.2174/156652408786733711 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuromyelitis Optica (NMO IgG+) and Genetic Susceptibility, Potential Ethnic Influences
Central Nervous System Agents in Medicinal Chemistry Monoclonal Antibodies: A Review
Current Clinical Pharmacology Microbes, Immunity and Multiple Sclerosis: An Update
Current Immunology Reviews (Discontinued) Mechanisms of Altered Cell Immunity and Cytotoxicity in COPD
Current Drug Targets Parasites in Rheumatoid Arthritis: Imminent Threat or Protective Effect?
Current Rheumatology Reviews Epigenetic Regulation of Regulatory T Cells in Kidney Disease and Transplantation
Current Gene Therapy Inhibitors of AP-1 and NF-κB Mediated Transcriptional Activation: Therapeutic Potential in Autoimmune Diseases and Structural Diversity
Current Medicinal Chemistry Emerging Treatment Strategies and Potential Therapeutic Targets in Primary Sjogrens Syndrome
Inflammation & Allergy - Drug Targets (Discontinued) Involvement of IL-1R/TLR Signalling in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
Current Molecular Medicine From Cannabis to Endocannabinoids in Multiple Sclerosis: A Paradigm of Central Nervous System Autoimmune Diseases
Current Drug Targets - CNS & Neurological Disorders Selenium and Autoimmune Diseases: A Review Article
Current Rheumatology Reviews Role of Renin-Angiotensin System in Inflammation, Immunity and Aging
Current Pharmaceutical Design A Common Pathway for All Autoimmune Diseases? The Unholy Alliance of Environment, Cell Death and Nucleic Acids
Current Immunology Reviews (Discontinued) Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Current Pharmaceutical Biotechnology Is Autoimmunity a Component of Natural Immunity to HIV?
Current HIV Research Antibody - Fc Receptor Interactions in Antimicrobial Functions
Current Immunology Reviews (Discontinued) A Comparison of Biological Activity of B Lymphocyte Stimulator (BLyS) Antagonist Peptibodies and the Elucidation of Possible BLyS Binding Sites
Protein & Peptide Letters NF-κB, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Challenge of Mesenchymal Stem Cells Against Diabetic Foot Ulcer
Current Stem Cell Research & Therapy Target Therapies in Systemic Lupus Erythematosus: Current State of the Art
Mini-Reviews in Medicinal Chemistry